Viveve Medical, Inc. (VIVE): Price and Financial Metrics


Viveve Medical, Inc. (VIVE): $0.41

0.00 (0.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VIVE Stock Summary

  • VIVE has a market capitalization of $4,396,781 -- more than approximately only 0.71% of US stocks.
  • VIVEVE MEDICAL INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 92.61% of US listed stocks.
  • VIVE's price/sales ratio is 0.64; that's higher than the P/S ratio of merely 20.95% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to VIVEVE MEDICAL INC are BFLY, VRAR, AMWL, BLZE, and AXDX.
  • VIVE's SEC filings can be seen here. And to visit VIVEVE MEDICAL INC's official web site, go to www.viveve.com.

VIVE Valuation Summary

  • In comparison to the median Healthcare stock, VIVE's EV/EBIT ratio is 102.33% lower, now standing at -0.2.
  • Over the past 153 months, VIVE's price/sales ratio has gone down 0.1.

Below are key valuation metrics over time for VIVE.

Stock Date P/S P/B P/E EV/EBIT
VIVE 2022-11-25 0.7 3.8 -0.2 -0.2
VIVE 2022-11-23 0.7 3.8 -0.2 -0.2
VIVE 2022-11-22 0.7 3.8 -0.2 -0.2
VIVE 2022-11-21 0.7 3.8 -0.2 -0.2
VIVE 2022-11-18 0.7 3.8 -0.2 -0.2
VIVE 2022-11-17 0.7 4.0 -0.2 -0.2

VIVE Growth Metrics

    The 5 year price growth rate now stands at -99.84%.
  • Its year over year revenue growth rate is now at 17.64%.
  • Its 3 year revenue growth rate is now at -62.89%.
Over the past 33 months, VIVE's revenue has gone up $259,000.

The table below shows VIVE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 6.826 -16.232 -28.135
2022-06-30 6.758 -15.545 -28.86
2022-03-31 6.617 -14.712 -26.925
2021-12-31 6.426 -12.878 -26.718
2021-09-30 6.667 -11.949 -24.967
2021-06-30 6.575 -12.033 -22.707

VIVE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VIVE has a Quality Grade of F, ranking ahead of 4.15% of graded US stocks.
  • VIVE's asset turnover comes in at 0.243 -- ranking 139th of 186 Medical Equipment stocks.
  • PETV, INO, and POAI are the stocks whose asset turnover ratios are most correlated with VIVE.

The table below shows VIVE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.243 0.157 -1.501
2021-03-31 0.237 0.089 -1.678
2020-12-31 0.279 0.054 -1.690
2020-09-30 0.224 -0.014 -2.471
2020-06-30 0.194 -0.079 -1.758
2020-03-31 0.198 0.025 -1.358

VIVE Price Target

For more insight on analysts targets of VIVE, see our VIVE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.63 Average Broker Recommendation 1.25 (Strong Buy)

VIVE Stock Price Chart Interactive Chart >

Price chart for VIVE

VIVE Price/Volume Stats

Current price $0.41 52-week high $1.65
Prev. close $0.41 52-week low $0.40
Day low $0.41 Volume 19,931
Day high $0.42 Avg. volume 117,355
50-day MA $0.57 Dividend yield N/A
200-day MA $0.77 Market Cap 4.44M

Viveve Medical, Inc. (VIVE) Company Bio


Viveve Medical, Inc. designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal laxity. The company was founded in 2005 and is based in Sunnyvale, California.


VIVE Latest News Stream


Event/Time News Detail
Loading, please wait...

VIVE Latest Social Stream


Loading social stream, please wait...

View Full VIVE Social Stream

Latest VIVE News From Around the Web

Below are the latest news stories about VIVEVE MEDICAL INC that investors may wish to consider to help them evaluate VIVE as an investment opportunity.

Viveve Medical Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

Viveve Medical ( NASDAQ:VIVE ) Third Quarter 2022 Results Key Financial Results Revenue: US$1.68m (up 4.2% from 3Q...

Yahoo | November 13, 2022

Viveve Medical, Inc. (VIVE) Q3 2022 Earnings Call Transcript

Viveve Medical, Inc. (NASDAQ:NASDAQ:VIVE) Q3 2022 Results Conference Call November 10, 2022 05:00 PM ET Company Participants Jeannie Swindle - Senior Director, Corporate Communications…

Seeking Alpha | November 10, 2022

Viveve Medical GAAP EPS of -$0.59 beats by $0.07, revenue of $17M beats by $15.29M

Viveve Medical press release (VIVE): Q3 GAAP EPS of -$0.59 beats by $0.07.Revenue of $17M (+962.5% Y/Y) beats by $15.29M.Gross profit for the third quarter of 2022 was $0.5 million,…

Seeking Alpha | November 10, 2022

Viveve Medical, Inc.: Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Total revenue of $1.7 million in Q3 including sale of 3,100 disposable treatment tipsPURSUIT clinical trial completion expected by year-endConference call to be hosted by Company at 5:00 PM ET toda…

Finanz Nachrichten | November 10, 2022

Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today reported financial results for the quarter ended September 30, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today.

Yahoo | November 10, 2022

Read More 'VIVE' Stories Here

VIVE Price Returns

1-mo -26.30%
3-mo -51.77%
6-mo -43.91%
1-year -73.38%
3-year -95.14%
5-year -99.99%
YTD -64.04%
2021 -75.74%
2020 -62.70%
2019 -98.80%
2018 -78.87%
2017 -3.50%

Continue Researching VIVE

Want to see what other sources are saying about Viveve Medical Inc's financials and stock price? Try the links below:

Viveve Medical Inc (VIVE) Stock Price | Nasdaq
Viveve Medical Inc (VIVE) Stock Quote, History and News - Yahoo Finance
Viveve Medical Inc (VIVE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0816 seconds.